A rationally designed synthetic antimicrobial peptide against Pseudomonas-associated corneal keratitis:...

Area of Science:

• Ophthalmology
• Microbiology
• Biochemistry

Background:

• Contact lens wear increases risk of Pseudomonas-associated corneal keratitis.
• Topical antibiotics are insufficient for treating ocular infections.
• Novel strategies are needed to combat Pseudomonas-induced microbial keratitis.

Purpose of the Study:

• To investigate the hybrid peptide VR18 as a potential therapeutic agent against Pseudomonas-associated microbial keratitis.
• To elucidate the mechanism of action of VR18 against Pseudomonas membranes.
• To evaluate the efficacy of VR18 in various infection models.

Main Methods:

• Live cell Raman spectroscopy, NMR, and fluorescence microscopy were used to study VR18's interaction with Pseudomonas membranes.
• Sparsely tethered bilayer lipid membrane bacterial models were employed.
• In vivo, in vitro, and ex vivo models of Pseudomonas infection were utilized to assess peptide efficacy.

Main Results:

• VR18 demonstrated a bacterial-specific membrane disruption mechanism against Pseudomonas.
• The peptide exhibited high affinity and selectivity for Pseudomonas.
• VR18 showed potent therapeutic potential in preclinical models of infection.

Conclusions:

• The hybrid peptide VR18 is a potent therapeutic agent for preventing or treating Pseudomonas-associated microbial keratitis.
• VR18's mechanism involves direct disruption of bacterial membranes.
• Topical application of VR18 offers a promising strategy for managing ocular infections in contact lens wearers.